Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI

Lung Cancer

Volumn 89, Issue 3, 2015, Pages 357-359

  Klempner, Samuel J ^a   Bazhenova, Lyudmila A ^b   Braiteh, Fadi S ^c   Nikolinakos, Petros G ^d   Gowen, Kyle ^e   Cervantes, Claudia M ^a   Chmielecki, Juliann ^e   Greenbowe, Joel R ^e   Ross, Jeffrey S ^e,f   Stephens, Philip J ^e   Miller, Vincent A ^e   Ali, Siraj M ^e   Ou, Sai Hong Ignatius ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Division of Hematology and Medical Oncology   (United States)

^d University Cancer and Blood Center   (United States)

^e FOUNDATION MEDICINE   (United States)

^f ALBANY MEDICAL CENTER   (United States)

Author keywords

Acquired resistance; EGFR mutations; Non small cell lung cancer; Post progression; RET rearrangement

Indexed keywords

AFATINIB; B RAF KINASE; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; GEMCITABINE; NAVELBINE; PACLITAXEL; PEMETREXED; PROTEIN RET; PROTEIN TYROSINE KINASE INHIBITOR; SCATTER FACTOR RECEPTOR; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURGERY; CASE REPORT; CELL TRANSFORMATION; CHEMORADIOTHERAPY; EPITHELIAL MESENCHYMAL TRANSITION; EXON; FEMALE; GENE AMPLIFICATION; GENE DELETION; GENE FREQUENCY; GENE MUTATION; GENE REARRANGEMENT; GENOMICS; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER METASTASIS; LUNG LOBECTOMY; LUNG METASTASIS; LUNG PARENCHYMA; LYMPH NODE BIOPSY; MALE; MEDIASTINUM LYMPH NODE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WILD TYPE; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE COURSE; DRUG RESISTANCE; GENETICS; LUNG NEOPLASMS; MOLECULARLY TARGETED THERAPY; MUTATION; PATHOLOGY; PROCEDURES;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE REARRANGEMENT; GENOMICS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MUTATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-RET; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84938597193     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2015.06.021     Document Type: Article

References (14)

1. Sequist L.V., Waltman B.A., Dias-Santagata D., Digumarthy S., Turke A.B., Fidias P., et al. Sci. Transl. Med. 2011, 3(March (23)). (75) 75ra26.
2. Yu H.A., Arcila M.E., Rekhtman N., Sima C.S., Zakowski M.F., Pao W., et al. Clin. Cancer Res. 2013, 19:2240-2247.
3. Camidge D.R., Pao W., Sequist L.V. Acquired resistance to TKIs in solid tumours: learning from lung cancer. Nat. Rev. Clin. Oncol. 2014, 11:473-481.
4. Drilon A., Wang L., Arcila M.E., Balasubramanian S., Greenbowe J.R., Ross J.S., et al. Broad, hybrid capture-based next-generation sequencing identifies actionable genomic alterations in lung adenocarcinomas otherwise negative for such alterations by other genomic testing approaches. Clin. Cancer Res. 2015, (January (7)). [Epub ahead of print].
5. Drilon A., Wang L., Hasanovic A., Suehara Y., Lipson D., Stephens P., et al. Response to cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov. 2013, 3:630-635.
6. Falchook G.S., Ordóñez N.G., Bastida C.C., Stephens P.J., Miller V.A., Gaido L., et al. Effect of the RET Inhibitor vandetanib in a patient With RET fusion-positive metastatic non-small-cell lung cancer. J. Clin. Oncol. 2014, (November (3)). [Epub ahead of print].
7. Drilon A.E., Sima C.S., Somwar R., Smith R., Ginsberg M.S., Riely G.J., et al. Phase II. study of cabozantinib for patients with advanced RET-rearranged lung cancers. Clin. Oncol. 2015, 33. (suppl; abstr 8007).
8. Gainor J.F., Varghese A.M., Ou S.H., Kabraji S., Awad M.M., Katayama R., et al. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1683 patients with non-small cell lung cancer. Clin. Cancer Res. 2013, 19:4273-4281.
9. Ou S.H., Bartlett C.H., Mino-Kenudson M., Cui J., Iafrate A.J. Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology. Oncologist 2012, 17:1351-1375.
10. Karachaliou N., Mayo-de las Casas C., Queralt C., de Aguirre I., Melloni B., Cardenal F., et al. Association of EGFR L858R mutation in circulating free DNA with survival in the EURTAC trial. JAMA Oncol. 2015, 1:149-157.
11. Mulligan L.M. RET revisited: expanding the oncogenic portfolio. Nat. Rev. Cancer 2014, 14:173-186.
12. Dillon L.W., Pierce L.C., Lehman C.E., Nikiforov Y.E., Wang Y.H. DNA topoisomerases participate in fragility of the oncogene RET. PLoS One 2013, 8(9):e75741.
13. Mizukami T., Shiraishi K., Shimada Y., Ogiwara H., Tsuta K., Ichikawa H., et al. Molecular mechanisms underlying oncogenic RET fusion in lung adenocarcinoma. J. Thorac. Oncol. 2014, 9:622-630.
14. Sasaki T., Koivunen J., Ogino A., Yanagita M., Nikiforow S., Zheng W., et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res. 2011, 71:6051-6060.